Infilea

Clobetasol propionate, the active ingredient in Infilea, is a corticosteroid presented as a topical formulation for skin use. It is prescribed to reduce inflammation and scaling in various dermatologic conditions such as psoriasis, eczema, and other inflammatory skin disorders. The product conforms to European Union pharmaceutical standards and is intended for short‑term use under medical supervision.

GNH USA supplies Infilea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with robust quality‑assurance processes and regulatory expertise across EU and global markets.

Clobetasol propionate is used topically to manage inflammatory skin disorders. - Psoriasis: reduces scaling, erythema and plaque thickness. - Eczema (atopic dermatitis): alleviates itching and inflammation. - Seborrheic dermatitis: controls redness and flaking on scalp and face. - Lichen planus: diminishes lesions and pruritus. - Discoid lupus erythematosus: suppresses cutaneous inflammation and lesion progression.

Topical clobetasol can cause local and systemic adverse reactions, most of which are dose‑ and duration‑dependent.

Common Side Effects: - Burning or stinging sensation at the application site. - Pruritus or mild itching. - Dryness or peeling of the skin. - Erythema or mild redness. - Folliculitis or acne‑like eruptions.

Serious or Rare Side Effects: - Skin atrophy or thinning. - Telangiectasia (visible small blood vessels). - Secondary bacterial, fungal or viral skin infections. - Hypothalamic‑pituitary‑adrenal (HPA) axis suppression. - Hyperglycemia or worsening of diabetes. - Allergic contact dermatitis.

Clobetasol propionate should be used with caution and under medical guidance. - Duration of therapy: limit to the shortest effective period to reduce risk of systemic absorption. - Application area: avoid large surface areas or occlusive dressings unless directed. - Pre‑existing infections: treat bacterial, fungal or viral skin infections before initiating therapy. - Pediatric use: exercise heightened caution in children due to increased skin permeability. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Clobetasol propionate may interact with other agents that affect skin integrity or systemic corticosteroid levels.

Major Interactions (Avoid): - Systemic corticosteroids: concurrent use can increase risk of HPA‑axis suppression. - Potent CYP3A4 inhibitors applied to the same area: may raise local drug concentration.

Moderate Interactions (Monitor Closely): - Antifungal or antibacterial topical agents: monitor for additive irritation. - Skin‑lightening agents (e.g., hydroquinone): assess for increased irritation. - Immunosuppressive biologics: watch for heightened infection risk.